{"id":24943,"date":"2025-09-29T16:20:11","date_gmt":"2025-09-29T14:20:11","guid":{"rendered":"https:\/\/makingpharmaindustry.it\/non-categorizzato\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/"},"modified":"2025-09-29T16:28:21","modified_gmt":"2025-09-29T14:28:21","slug":"gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico","status":"publish","type":"post","link":"https:\/\/makingpharmaindustry.it\/en\/regulatory\/guidelines\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/","title":{"rendered":"A New Face for GMP"},"content":{"rendered":"

More than ten years after its last revision, Chapter 1 of the Good Manufacturing Practices (GMP)<\/strong> \u2013 the foundational document defining the requirements of the Pharmaceutical Quality System (PQS)<\/strong> \u2013 is undergoing a major overhaul. On 3 September 2025, the European Commission opened a public consultation<\/strong> on the new draft, which will remain open until 3 December 2025<\/strong>.<\/p>\n

The PQS is the backbone of any GMP-compliant manufacturing process and plays a key role in implementing a risk-based approach<\/strong>, which is now essential to ensure the quality, safety, and efficacy of medicines. The revision has two main objectives: to align the text with the latest scientific and technological knowledge<\/strong> and to harmonize it with international guidelines<\/strong>, particularly the ICH Q9(R1) on Quality Risk Management (QRM).<\/p>\n

Risk management at the core of quality systems<\/h2>\n

The main thread running through the revision is the strengthening of a systematic approach to risk management<\/strong> throughout the product lifecycle. The new text highlights how QRM must become a strategic, proactive tool capable of reducing variability in quality outcomes<\/strong>, supporting timely, informed decisions, and driving continuous improvement.<\/p>\n

Particular attention is given to the prevention of medicine shortages<\/strong>, an increasingly critical issue for regulators. The revised guidance stresses the importance of proactively identifying manufacturing and supply chain risks<\/strong>, including external factors such as problems with raw material suppliers or contract partners.<\/p>\n

PQS, knowledge, and early warning systems<\/h2>\n

Chapter 1 significantly expands the role of the PQS. In particular, paragraph 1.4 explicitly introduces the use of Quality Risk Management in the design and qualification of manufacturing systems<\/strong>, extending its application to every stage of the pharmaceutical lifecycle.<\/p>\n

The revised text also closely links risk management and knowledge management<\/strong>: together, these elements should form a robust early warning system<\/strong>, capable of monitoring evolving quality and manufacturing risks both internally and externally. This approach not only improves production resilience but also plays a crucial role in managing potential product shortages before they occur.<\/p>\n

More robust and meaningful Product Quality Reviews<\/h2>\n

Another key update concerns the Product Quality Review (PQR)<\/strong>, which becomes more flexible and comprehensive. When only a few batches are manufactured during a given year, the new text recommends including historical data from previous review periods<\/strong> to ensure a more solid and representative analysis of process consistency.<\/p>\n

The revision also mandates that a PQR must be performed even in the absence of production during the review period<\/strong>, including key parameters such as stability results, complaints, recalls, major deviations, and regulatory variations. Review timelines may be adjusted to reflect manufacturing realities, provided they are justified and supported by documented internal procedures.<\/p>\n

New opportunities for product grouping<\/h2>\n

Paragraph 1.11 introduces new grouping strategies<\/strong> for quality reviews, allowing products with the same active substance or manufactured on the same equipment to be reviewed together. However, such strategies must demonstrate that grouping improves process analysis and does not hinder the detection of negative trends for individual products.<\/p>\n

It remains unacceptable<\/strong> to base reviews solely on a representative or \u201cworst-case\u201d product. Grouping strategies must be defined in formal technical agreements<\/strong> between the marketing authorization holder and the manufacturer.<\/p>\n

QRM: formality, subjectivity, and knowledge<\/h2>\n

The revised text makes it clear that QRM is a systematic process that supports decision-making<\/strong> and should be applied throughout the entire product lifecycle. It also emphasizes the importance of managing subjectivity<\/strong> to preserve the effectiveness of risk-based decisions and of periodically reassessing QRM results<\/strong> in light of new knowledge and experience.<\/p>\n

An important clarification expands the definition of \u201cquality risk\u201d to include situations that may compromise product availability<\/strong>. Every player in the supply chain, from manufacturing to distribution, is responsible for managing such scenarios.<\/p>\n

A strategic text for the future of GMP<\/h2>\n

The revision of Chapter 1 of the GMP is far more than a technical update. It represents a cultural shift<\/strong> in how pharmaceutical quality is understood \u2013 from a control function to a strategic driver of risk management, innovation, and therapeutic continuity<\/strong>.<\/p>\n

For the European pharmaceutical industry, the new text is an invitation to adopt a more integrated, proactive, and knowledge-driven approach that supports technological progress and ensures the safe and reliable supply of medicines to patients.<\/p>\n

The public consultation will remain open until 3 December 2025<\/strong>. Organizations and professionals can submit their feedback via the EU Survey<\/strong> platform or through their relevant industrial associations. The European Industrial Pharmacists Group (EIPG)<\/strong> will coordinate a collective response on behalf of Europe\u2019s industrial pharmacists.<\/p>\n","protected":false},"excerpt":{"rendered":"

The revision of Chapter 1 of the GMP updates the European regulatory framework for pharmaceutical quality systems, expanding the role of risk management, knowledge management, and medicine shortage prevention. The public consultation remains open until 3 December 2025.<\/p>\n","protected":false},"author":32,"featured_media":24941,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[821],"tags":[],"class_list":{"0":"post-24943","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-guidelines"},"yoast_head":"\nGMP, la revisione del Capitolo 1<\/title>\n<meta name=\"description\" content=\"The revision of Chapter 1 of the GMP updates the European regulatory framework for pharmaceutical quality systems\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/makingpharmaindustry.it\/en\/regulatory\/guidelines\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GMP, la revisione del Capitolo 1\" \/>\n<meta property=\"og:description\" content=\"The revision of Chapter 1 of the GMP updates the European regulatory framework for pharmaceutical quality systems\" \/>\n<meta property=\"og:url\" content=\"https:\/\/makingpharmaindustry.it\/en\/regulatory\/guidelines\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/\" \/>\n<meta property=\"og:site_name\" content=\"MakingPharmaIndustry\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-29T14:20:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-29T14:28:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/09\/ChatGPT-Image-29-set-2025-14_56_28-1024x683.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"683\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Valentina Parrella\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Valentina Parrella\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/regulatory\/guidelines\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/regulatory\/guidelines\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/\"},\"author\":{\"name\":\"Valentina Parrella\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f\"},\"headline\":\"A New Face for GMP\",\"datePublished\":\"2025-09-29T14:20:11+00:00\",\"dateModified\":\"2025-09-29T14:28:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/regulatory\/guidelines\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/\"},\"wordCount\":726,\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/regulatory\/guidelines\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/09\/ChatGPT-Image-29-set-2025-14_56_28.png\",\"articleSection\":[\"Guidelines\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/regulatory\/guidelines\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/regulatory\/guidelines\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/\",\"name\":\"GMP, la revisione del Capitolo 1\",\"isPartOf\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/regulatory\/guidelines\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/regulatory\/guidelines\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/09\/ChatGPT-Image-29-set-2025-14_56_28.png\",\"datePublished\":\"2025-09-29T14:20:11+00:00\",\"dateModified\":\"2025-09-29T14:28:21+00:00\",\"author\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f\"},\"description\":\"The revision of Chapter 1 of the GMP updates the European regulatory framework for pharmaceutical quality systems\",\"breadcrumb\":{\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/regulatory\/guidelines\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/makingpharmaindustry.it\/en\/regulatory\/guidelines\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/regulatory\/guidelines\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/#primaryimage\",\"url\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/09\/ChatGPT-Image-29-set-2025-14_56_28.png\",\"contentUrl\":\"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/09\/ChatGPT-Image-29-set-2025-14_56_28.png\",\"width\":1536,\"height\":1024},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/regulatory\/guidelines\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/makingpharmaindustry.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"A New Face for GMP\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#website\",\"url\":\"https:\/\/makingpharmaindustry.it\/en\/\",\"name\":\"MakingPharmaIndustry\",\"description\":\"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f\",\"name\":\"Valentina Parrella\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g\",\"caption\":\"Valentina Parrella\"},\"url\":\"https:\/\/makingpharmaindustry.it\/en\/author\/valentina-parrella\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GMP, la revisione del Capitolo 1","description":"The revision of Chapter 1 of the GMP updates the European regulatory framework for pharmaceutical quality systems","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/makingpharmaindustry.it\/en\/regulatory\/guidelines\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/","og_locale":"en_US","og_type":"article","og_title":"GMP, la revisione del Capitolo 1","og_description":"The revision of Chapter 1 of the GMP updates the European regulatory framework for pharmaceutical quality systems","og_url":"https:\/\/makingpharmaindustry.it\/en\/regulatory\/guidelines\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/","og_site_name":"MakingPharmaIndustry","article_published_time":"2025-09-29T14:20:11+00:00","article_modified_time":"2025-09-29T14:28:21+00:00","og_image":[{"width":1024,"height":683,"url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/09\/ChatGPT-Image-29-set-2025-14_56_28-1024x683.png","type":"image\/png"}],"author":"Valentina Parrella","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Valentina Parrella","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/makingpharmaindustry.it\/en\/regulatory\/guidelines\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/#article","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/regulatory\/guidelines\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/"},"author":{"name":"Valentina Parrella","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f"},"headline":"A New Face for GMP","datePublished":"2025-09-29T14:20:11+00:00","dateModified":"2025-09-29T14:28:21+00:00","mainEntityOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/regulatory\/guidelines\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/"},"wordCount":726,"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/regulatory\/guidelines\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/09\/ChatGPT-Image-29-set-2025-14_56_28.png","articleSection":["Guidelines"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/makingpharmaindustry.it\/en\/regulatory\/guidelines\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/","url":"https:\/\/makingpharmaindustry.it\/en\/regulatory\/guidelines\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/","name":"GMP, la revisione del Capitolo 1","isPartOf":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/makingpharmaindustry.it\/en\/regulatory\/guidelines\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/#primaryimage"},"image":{"@id":"https:\/\/makingpharmaindustry.it\/en\/regulatory\/guidelines\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/#primaryimage"},"thumbnailUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/09\/ChatGPT-Image-29-set-2025-14_56_28.png","datePublished":"2025-09-29T14:20:11+00:00","dateModified":"2025-09-29T14:28:21+00:00","author":{"@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f"},"description":"The revision of Chapter 1 of the GMP updates the European regulatory framework for pharmaceutical quality systems","breadcrumb":{"@id":"https:\/\/makingpharmaindustry.it\/en\/regulatory\/guidelines\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/makingpharmaindustry.it\/en\/regulatory\/guidelines\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/makingpharmaindustry.it\/en\/regulatory\/guidelines\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/#primaryimage","url":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/09\/ChatGPT-Image-29-set-2025-14_56_28.png","contentUrl":"https:\/\/makingpharmaindustry.it\/wp-content\/uploads\/2025\/09\/ChatGPT-Image-29-set-2025-14_56_28.png","width":1536,"height":1024},{"@type":"BreadcrumbList","@id":"https:\/\/makingpharmaindustry.it\/en\/regulatory\/guidelines\/gmp-la-revisione-del-capitolo-1-aggiorna-il-cuore-del-sistema-qualita-farmaceutico\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/makingpharmaindustry.it\/en\/"},{"@type":"ListItem","position":2,"name":"A New Face for GMP"}]},{"@type":"WebSite","@id":"https:\/\/makingpharmaindustry.it\/en\/#website","url":"https:\/\/makingpharmaindustry.it\/en\/","name":"MakingPharmaIndustry","description":"Luogo di incontro\u00a0per approfondire e discutere le pi\u00f9 importanti tematiche del mondo Pharma, dalla ricerca e sviluppo al manufacturing, dal mercato al business","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/makingpharmaindustry.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/makingpharmaindustry.it\/en\/#\/schema\/person\/6c2a2cb5a6dc47527ff5eb31dab7d42f","name":"Valentina Parrella","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9489e527cae2d980412b4296f66093487551a8e1010c544334080d6b66e72eeb?s=96&d=mm&r=g","caption":"Valentina Parrella"},"url":"https:\/\/makingpharmaindustry.it\/en\/author\/valentina-parrella\/"}]}},"_links":{"self":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/24943","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/comments?post=24943"}],"version-history":[{"count":2,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/24943\/revisions"}],"predecessor-version":[{"id":24945,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/posts\/24943\/revisions\/24945"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media\/24941"}],"wp:attachment":[{"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/media?parent=24943"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/categories?post=24943"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/makingpharmaindustry.it\/en\/wp-json\/wp\/v2\/tags?post=24943"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}